Peginterferon alpha-based therapy for chronic hepatitis b focusing on hbsag clearance or seroconversion: A meta-analysis of controlled clinical trials

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Li, Wen Cong ^a   Wang, Mao Rong ^b   Kong, Ling Bo ^a   Ren, Wei Guang ^a   Zhang, Yu Guo ^a   Nan, Yue Min ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Nanjing 81 Hospital   (China)

Author keywords

hbsag; Hepatitis B; Lamivudine; Ninterferon; Peginterfero

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE SEQUENCE; DRUG EFFICACY; HEPATITIS B; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOMES RESEARCH; PATIENT SELECTION; PUBLISHING; SEROCONVERSION; TREATMENT DURATION; VIRAL CLEARANCE; DRUG COMBINATION; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 79958038529     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-165     Document Type: Article

References (44)

1. Wilkins T, Zimmerman D, Schade RR. Hepatitis B: Diagnosis and Treatment. Am Fam Physician 2010, 81:965-972.
2. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008, 14:6902-6910. 10.3748/wjg.14.6902, 2773851, 19058323.
3. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009, 373:582-592. 10.1016/S0140-6736(09)60207-5, 19217993.
4. Zoulim F, Perrillo R. Hepatitis B: Reflections on the current approach to antiviral therapy. J Hepatol 2008, 48:S2-S19.
5. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527. 10.1053/jhep.2002.33638, 12029639.
6. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422-1427. 10.1056/NEJM199605303342202, 8618580.
7. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34:617-624. 10.1053/jhep.2001.27834, 11584355.
8. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263-270.
9. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37:756-763. 10.1053/jhep.2003.50148, 12668967.
10. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857-861. 10.1002/hep.20110, 14999707.
11. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J, Rosenberg W, Valla D, . EASL Jury EASL International Consensus Conference on Hepatitis B, 13-14 September, 2002, Geneva, Switzerland: consensus statement (long version). J Hepatol 2003, 39:S3-S25. EASL Jury.
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007, 45:507-539. 10.1002/hep.21513, 17256718.
13. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998, 93:896-900. 10.1111/j.1572-0241.1998.00272.x, 9647014.
14. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46:45-52. 10.1016/j.jhep.2006.08.021, 17107734.
15. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, . Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group Peginterferon alfa-2a, Lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695. 10.1056/NEJMoa043470, 15987917, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
16. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N, . Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group Peginterferon alfa-2a alone, Lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217. 10.1056/NEJMoa040431, 15371578, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.
17. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S, . Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a. Gastroenterology 2009, 136:2169-2179. 10.1053/j.gastro.2009.03.006, 19303414, Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group.
18. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ. Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone. Ann Intern Med 2005, 142:240-250.
19. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-Term Follow-Up of Peginterferon and Lamivudine Combination Treatment in HBeAg-Positive Chronic Hepatitis B. Hepatology 2005, 41:1357-1364. 10.1002/hep.20695, 15880608.
20. Tian YL, Zhao W, Shen L, Liu W, Chang JB, Fang ZX, Yin WW, Wang L, Sun XB, Yang YJ. Pegylated interferon alpha 2a in treating chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2006, 14:806-810.
21. Cui JJ, Fan P, Jiang XL, Xu C, He Q, Zhou BP. Efficacy and safety of peginterferon alfa-2a treatment in patients with HBeAg-positive chronic hepatitis B. Chinese J Exp Clin Virol 2006, 20:331-333.
22. Li ZQ, Sun CY, Wu SH, Yu ZJ, Jiang HQ. Evaluation of Efficacy of Peg-interferonα-2a Therapy in patients with HBeAg Positive Chronic Hepatitis B. Journal of Medical Forum 2010, 31:51-53.
23. Guan LJ, Fan RS, Chen JF. Pegylated interferon in treating HBeAg negative chronic hepatitis B patients. Clinical Medical Journal of China 2006, 13:959.
24. Lau GK. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver International 2009, 29:125-129.
25. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662. 10.1002/hep.23190, 19714720.
26. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50:227-242. 10.1016/j.jhep.2008.10.001, 19054588, European Association for the Study of the Liver.
27. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12. 10.1016/0197-2456(95)00134-4, 8721797.
28. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW, . HBV 99-01 Study Group; Rotterdam Foundation for Liver Research Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129. 10.1016/S0140-6736(05)17701-0, 15639293, HBV 99-01 Study Group; Rotterdam Foundation for Liver Research.
29. Shi XF. The Primary Clinical Study of Peginterferon Alfa-2a in the Treatment the Patients with HBeAg-Positive Chronic Hepatitis B and with Drug Fast to Lamivudine. CNKI: CDMD 1.2006.176314.
30. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg Loss after Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b. Gastroenterology 2008, 135:459-467. 10.1053/j.gastro.2008.05.031, 18585385.
31. Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersöz G, Ozenirler S, Kalayci C, Poturoglu S, Cakaloglu Y, Okten A. Pegylated Interferon Alfa-2b Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine Combination Therapy for Patients with Hepatitis B Virus E Antigen-Negative Chronic Hepatitis B. Antimicrob Agents Chemother 2007, 51:3020-3022. 10.1128/AAC.00088-07, 1932537, 17517832.
32. Huang ZL, Zhao ZX, Deng H, Zhang YF, Lu CR, Gao ZL. A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2010, 18:419-422.
33. Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M. A randomized controlled trail of pegylated interferon-alpha 2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antiviral Therapy 2009, 14:1165-1174.
34. Marcellin P, Lada O, Asselah T. Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine. Hepatology Research 2007, 37:S55-S61. 10.1111/j.1872-034X.2007.00106.x, 17627637.
35. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009, 50:289-295. 10.1016/j.jhep.2008.10.017, 19070393.
36. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010, 139:491-498. 10.1053/j.gastro.2010.03.059, 20381492.
37. Tang SB, Ke CZ, Kang J, Li D, Chen Y. Investigation of PEG-IFNα-2a treatment of chronic hepatitis B patients who failed to lamivudine therapy. J Cl in Hepatol 2007, 10:311-312.
38. Hou J, Sun J, Xie Q, Li X, Zhang J, Wang Y, Wang H, Jak YL, Chen S, Jia J, Sheng J, Chan H, Wang J, Li M, Jiang M, Popescu M, Sung J. A prospective, randomized study of efficacy and safety of peginterferon alfa-2a versus adefovir dipivoxil in treating lamivudine-resistant HBeAg-positive CHB. J Hepatol 2009, 50:S330.
39. Chen XF, Chen XP, Huang J, Chen W-L, Chen R. Comparison of peginterferon alfa-2a versus entecavir in patients with HBeAg-positive chronic hepatitis B with mildly elevated alanine aminotransferase levels. J Hepatol 2009, 50:S328.
40. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Popescu M, Farci P, Yurdaydin C, Wu J, Lau GKK. Virological and biochemical response in patients with HBeAg negative chronic hepatitis B treated with peginterferon alfa-2a (40 kd) with or without lamivudine: results of 4-year follow-up. J Hepatol 2008, 48:S48.
41. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Lau GKK, Farci P, Yurdaydin C, Gurel S, Wu J, Popescu M. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a ± lamivudine: results of 5-year post-treatment follow up. J Hepatol 2009, 50:S336.
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL, . Adefovir Dipivoxil 438 Study Group Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673-2681. 10.1056/NEJMoa042957, 15987916, Adefovir Dipivoxil 438 Study Group.
43. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, . BEHoLD AI463027 Study Group Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020. 10.1056/NEJMoa051287, 16525138, BEHoLD AI463027 Study Group.
44. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455. 10.1056/NEJMoa0802878, 19052126.